ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Cited by (999)

Items 801–900 of 999

1. Litmus-Body: A Molecularly Targeted Sensor for Cell-Surface pH Measurements
   Joe Chin‐Hun Kuo, Marc C. Goudge, Ann E. Metzloff, Lingting Huang, Marshall J. Colville, Sangwoo Park, Warren R. Zipfel, Matthew J. Paszek · 2020 · ACS Sensors
2. Embryonic lethality and defective mammary gland development of activator‐function impaired conditional knock‐in Erbb3 V943R mice
   Kate Senger, Wenlin Yuan, Meredith S. Sagolla, Jonas Doerr, Brad N. Bolon, James M. Ziai, Kai‐Hui Sun, Søren Warming, Merone Roose‐Girma, Na Zhang et al. · 2020 · Advanced Genetics
3. Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model
   Mojgan Ghaedi, Forough Golsaz‐Shirazi, Tannaz Bahadori, Jalal Khoshnoodi, Sahar Mortezagholi, Mahmood Jeddi‐Tehrani, Mohammad Mehdi Amiri, Fazel Shokri · 2022 · Journal of Cancer Research and Clinical Oncology
4. Pathways of Targeted Therapy for Colorectal Cancer
   Sameeksha Jain, Arpana Purohit, Prakhar Nema, Harshna Vishwakarma, Arzoo Qureshi, Prateek Kumar Jain · 2022 · Journal of Drug Delivery and Therapeutics
5. The functional switch of TGF-β signaling in breast cancer
   Qiaoni Shi, Ye‐Guang Chen · 2019 · Oncotarget
6. The network response to Egf is tissue-specific
   Beatrice W. Awasthi, João A. Paulo, Deborah L. Burkhart, Ian R.L. Smith, Ryan L. Collins, J. Wade Harper, Steven P. Gygi, Kevin M. Haigis · 2025 · iScience
7. The peptide-Au clusters inhibit EGFR exon 19 deletion mutant non-small cell lung cancer
   Wencong Zhao, Wendi Huo, Haoran Dang, Zhongying Du, Qing Yuan, Kai Cao, Xueyun Gao · 2025 · Nano Today
8. RNF213 ‐Dependent EGFR and HER2 Activation Regulates Specific Downstream Signaling Pathways in Human Cancer Cells
   Intisar Fouad Ali Mursi, Jungmi Choi, Qianying Huang, Minsoo Kim, Seiji Masuda, James Hejna, Yohei Mineharu, Akio Koizumi, Tohru Tezuka, Shohab Youssefian · 2025 · Genes to Cells
9. Genome wide mapping of nuclear mitochondrial DNA sequences (NUMTs) and their functionality in domestic water buffalo (Bubalus bubalis)
   Rangasai Chandra Goli, Karan Mahar, Kiyevi G Chishi, Tanuj Gunturu, Vikas Diwakar, Amit Kumar, Ganesh Narayanrao Aderao, K. C. Nikhil, Muralidhar Metta, Nidhi Sukhija et al. · 2025 · Conservation Genetics Resources
10. Artificial Intelligence in Ultrasound Diagnosis of Liver Nodules: A Comprehensive Review of B-Mode and Contrast-enhanced Applications
    Xiaoling Yu, Zheng lai Song, Xue yong Chang, Jie Yu, Ping Liang · 2025 · Advanced ultrasound in diagnosis and therapy
11. Computational profiling of flavonoids against key breast cancer targets: an in-silico exploration
    Stephen A. Praise, M. M. Olusanya, Ajiboye Kolawole, Adeoye B. Awolesi, Christiana Oluwakunmisola Igbin, Gladys D. Egunjobi, Oluwafemi Shittu Bakare, I.C. Ezeuchenne, J A Musibau · 2025 · In Silico Pharmacology
12. Alternative Splicing-Mediated Resistance to Antibody-Based Therapies: Mechanisms and Emerging Therapeutic Strategies
    Sanga Choi, Jieun Kang, Jung‐Hyun Kim · 2025 · International Journal of Molecular Sciences
13. Nanoparticle-mediated radiosensitization in colorectal cancer radiation therapy: A narrative review on mechanisms, clinical translation, and future perspectives
    Sina Taghvimi, Elahe Soltani Fard, Alireza Baghrobehbahani, Mohsen Shafiee, Vahid Zarezadeh, Mina Pourhabib Mamaghani, Mohammadreza Nazarian, Nahid Chegeni, Ahmad Movahedpour, Pegah Mousavi et al. · 2026 · Applied Radiation and Isotopes
14. Exploring tyrosine kinase inhibitors for HER2-positive breast cancer: comprehensive review on a complete pharmacology-molecular mechanisms, safety profiles, and insights from preclinical and clinical studies
    Meghraj Vivekanand Suryawanshi, Rukaiya T. Girase, Vishal S. Bagul, Pranjal P. Gujarathi · 2026 · Clinical & Translational Oncology
15. Single-cell transcriptomic analysis reveals that the circRNA circGCLM promotes tumorigenesis and confers cisplatin resistance in NSCLC through the miR-505-3p/ERBB4 axis
    Yirou Ma, Baiqing Huang, Haiyang Wang, Mengchao Xue, Yiyang Liu, Yibo Jin, Chunping Wang, Shaorui Gu, Yongxin Zhou · 2026 · Translational Oncology
16. Secretory autophagy mediates SLC16A3/MCT4-dependent lactate secretion to drive metastatic progression in triple-negative breast cancer
    Shan‐Ying Wu, Hung-Ju Lin, Kai-Ying Lan, Hong‐Chen Chen, Chao-Hsiung Lin, Chih-Yi Hsu, Yi‐Jang Lee, Yen-Yu Chou, Yeh‐Shiu Chu, Wei-Chung Chiang et al. · 2026 · Autophagy
17. Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants
    Paul‐Yang Lin, Bing-Syuan Zeng, Jiann-Jy Chen, Bing‐Yan Zeng, Mein‐Woei Suen, Chao-Ming Hung, Chih-Wei Hsu, Brendon Stubbs, Yen-Wen Chen, Tien-Yu Chen et al. · 2026 · Journal of Hematology & Oncology
18. Complex interaction of adipokines in breast cancer and anti-tumour immunity; a new paradigm for cancer treatment
    Peng Tan, Mingrui Xie, Eleftherios Sfakianakis · 2021 · Cancer Research and Cellular Therapeutics
19. Therapeutic Intervention of Signaling Pathways in Colorectal Cancer
    Vikas Chandra, Ashutosh Tiwari, Rajat Pratap Singh, Kartiki Vasant Desai · 2022 · Springer eBooks
20. Crosstalk between TGF-β and EGF receptors via direct phosphorylation
    Aristidis Moustakas · 2024 · The Journal of Cell Biology
21. HER2 puzzle pieces: Non-Coding RNAs as keys to mechanisms, chemoresistance, and clinical outcomes in Ovarian cancer
    Fangwei Yang, Lixiang Yan, Junnan Ji, Yunxia Lou, Jinlu Zhu · 2024 · Pathology - Research and Practice
22. Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts
    Cindy Q. Zhou, Ariel Li, Kaoru Ri, Ahmed S. Sultan, Hening Ren · 2024 · Cancer Research Communications
23. Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers
    Laura Muñoz‐Moreno, María Isabel Gómez-Calcerrada, María Isabel Arenas, María José Carmena, Juan Carlos Prieto, Andrew Victor Schally, Ana Maria Bajo · 2024 · International Journal of Molecular Sciences
24. Bladder Cancer Treatments in the Age of Personalized Medicine: A Comprehensive Review of Potential Radiosensitivity Biomarkers
    Charbel Feghaly, Rafka Challita, Hanine Bou Hadir, Tala Mobayed, Tarek Al Bitar, Mohammad Harbi, Hala Ghorayeb, Rana El-Hassan, Larry Bodgi · 2024 · Biomarker Insights
25. Machine learning based ultrasomics noninvasive predicting EGFR expression status in hepatocellular carcinoma patients
    Yujing Ma, Shaobo Duan, Shanshan Ren, Didi Bu, Yahong Li, Xiguo Cai, Lianzhong Zhang · 2024 · Frontiers in Medicine
26. Current Development of Virotherapy in Breast Cancer: A Brief Review
    I Gede Aswin Parisya Sasmana, Putu Mirah Wahyu Subagia Putri, Ni Wayan Sucindra Dewi, I. Supadmanaba, Desak Made Wihandani · 2024 · Acta Medica Bulgarica
27. Neratinib and the Role of Anti‐ HER2 Therapy in Salivary Duct Carcinoma
    Martina Napolitano, Lucia Trudu, Enrica Martinelli, Chiara Santini, Massimo Dominici, Federica Bertolini · 2025 · Cancer Reports
28. SLC26A9 promotes the initiation and progression of breast cancer by activating the PI3K/AKT signaling pathway
    Zhiyuan Ma, Hu Wang, Zhengxing Zhou, Chengli Lu, Minglin Zhang, Renmin Mu, Chengmin Zhang, Zhiqiang Yi, Zilin Deng, Yingying Zhao et al. · 2025 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
29. Bistable dynamics of TAN-NK cells in tumor growth and control of radiotherapy-induced neutropenia in lung cancer treatment
    Donggu Lee, Sun‐Ju Oh, Sean Edward Lawler, Yangjin Kim · 2025 · Mathematical Biosciences & Engineering
30. Unveiling Epigenetic Regulatory Elements Associated with Breast Cancer Development
    Marta Jardanowska-Kotuniak, Michał Dramiński, Michał Wlasnowolski, Marcin Łapiński, Kaustav Sengupta, Abhishek Agarwal, Adam Filip, Nimisha Ghosh, Véra Pancaldi, Marcin Grynberg et al. · 2025 · International Journal of Molecular Sciences
31. Single-Cell Omics: Strategies Towards Theranostic Biomarker Discovery Along the Continuum of Premalignant to Invasive Disease in Oncology
    Sinem Nalbantoğlu, Hakima Amri · 2019 · Elsevier eBooks
32. EGFR (ErbB) Signaling Pathways in Pancreatic Cancer Pathogenesis
    Monique Williams, Gwen Alyce Lomberk, Raul A. Urrutia · 2017 · Springer eBooks
33. Fundamental Pathways in Breast Cancer 1: Signaling from the Membrane
    Yekaterina Poloz, Ryan J.O. Dowling, Vuk Stambolic · 2017 · Springer eBooks
34. Neuregulin Signaling in the Tumor Microenvironment
    Ruxue Jia, Hu Zhao, Shuiliang Wang · 2020 · Advances in experimental medicine and biology
35. A rotamer relay information system in the epidermal growth factor receptor–drug complexes reveals clues to new paradigm in protein conformational change
    Tareq Hameduh, Michal Mokry, Andrew David Miller, Vojtěch Adam, Zbyněk Heger, Yazan Haddad · 2021 · Computational and Structural Biotechnology Journal
36. Molecular Progression of Breast Cancer and Personalized Medicine in Terms of Clinical Trials
    Somia Liaqat, Mubashar Hussain, Kiran Aftab, Maryam Khalid, Saima Shakil Malik · 2022 · Springer eBooks
37. Her2low breast cancer. New opportunities and challenges
    Nataliia Verovkina, Sergii A. Lyalkin, Liubov A. Syvak · 2022 · Український радіологічний та онкологічний журнал
38. Construction and validation of a novel prognostic signature for cutaneous melanoma based on ferroptosis-related genes
    Wenna Guo, Xue Bing Wang, Yan-ting Yann Zhang, Hongtao Liu, Shanshan Ma, Fangxia Guan · 2023 · Heliyon
39. Notch and Breast Cancer Metastasis
    Yu Zhang, Huan Deng · 2018 · Preprints.org
40. Aberrant Signaling Pathways in Cancer
    Luca Grumolato, Stuart A. Aaronson · 2017 · Wiley eBooks
41. ErbB Receptor Stimulation Is Required for Mouse Colon Adenoma Organoids to Form Crypts
    Chin Wee Tan, Ruiyan Zhu, Serena R. Kane, Michelle Au, Xiaoyu Zhang, Yumiko Hirokawa, Maree C. Faux, Antony Wilks Burgess · 2021 · Research Square
42. Treatments That Block Proteins Involved in Cell Communication
    Elaine Vickers PhD · 2018 · Wiley eBooks
43. Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in HER2-mutant breast cancer
    Arnaldo Marín, Abdullah Al Mamun, Hiroaki Akamatsu, Dan Ye, Dhivya R. Sudhan, Benjamin P. Brown, Lisa D. Eli, Katherine Marcelain, Jens Meiler, Carlos L. Arteaga et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
44. Aberrant Signaling Pathways in Cancer
    Luca Grumolato, Stuart A. Aaronson · 2022 · Wiley eBooks
45. One Novel BiP/GRP78 Inhibitor YUM70 Induces GSDME Dependent Pyroptosis and Enhances Sensitivity To EGFR Inhibitors in cholangiocarcinoma and hepatocellular carcinoma
    Lei Sun, Yanan Liu, Hao Zhou, Mingyan Zhang, Xuelei Cao, Jian Zhang · 2022 · Research Square
46. Proliferation/Differentiation in intestinal organoids as a balance of ligand-modulated EGFR traffic
    Mario O. Caracci, Sabrina Seidler, Luis Manuel Muñoz-Nava, Birga Soetje, Kirsten Michel, Philippe I. H. Bastiaens · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
47. Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies
    Henrykowska, Gabriela, Bartusik-Aebisher, Dorota, Dynarowicz, Klaudia, Ramesh, Tamil Selvan, Smolak, Barbara, Aebisher, David · 2026 · Pharmaceuticals
48. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines
    Hiba M. Zalloum, Tuka AbuThiab, Tareq Hameduh, Sara AlBayyari, Waleed A. Zalloum, Bashaer Abu‐Irmaileh, Mohammad Suleiman Mubarak, Malek Zihlif · 2019 · Breast Cancer
49. Novel mutations of SRPX facilitate the stemness and malignant progression of glioma
    Siyuan Tang, Chunhui Qu, Mingyu Zhang, Peijun Zhou, Xingzhi Peng, Zhuan Zhou, Liangfang Shen, Lifang Yang · 2025 · British Journal of Cancer
50. Antibody treatments for digestive cancers: Past, present, and future
    Ikrame Dadi, Thibault Mazard, Lena-Marie Schmitt, Tommy Chastel, Andrei Turtoï, Marie‐Alix Poul, Sophie Pattingre · 2025 · Seminars in Oncology
51. PRAME-AS lncRNA, regulated by MZF1, modulates PRAME expression and cell stemness
    Zahra Hosseininia, Hesam Dehghani · 2025 · PLoS ONE
52. Multi-omics analysis identifies the unique high-FDCSP basal cells in triple-negative breast cancer
    Xinya Lu, Zhen Chen, Ying Shao · 2025 · Experimental Biology and Medicine
53. NoxO1 promotes endosome formation and reduces intracellular vesicle processing
    Maureen Hebchen, Falk Herwig, Tim Schader, Manuela Spaeth, Niklas Müller, Katrin Schröder · 2025 · Redox Biology
54. Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies
    Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto-Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Khani Farahani, Deepankar Chakroborty, Nikol Dibus et al. · 2025 · Molecular Oncology
55. In Silico Analysis of H-Lys-Asp-OH Dipeptide: DFT Optimization, Frontier Orbitals, Electrostatic Potential, EGFR/HER2 Docking and ADMET Profiling
    Aliye Demet Demirağ · 2025 · Cumhuriyet Science Journal
56. EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators
    Naiara Perurena, Marina Watanabe, Amy E. Schade, William R. Brown, Elizabeth Y. Luo, Alycia Gardner, Alexandra Indeglia, Akiko Yoshinaga, Rhea Sahu, Yoona Yang et al. · 2026 · Cancer Research
57. HOXB5 in precision oncology: regulatory networks, functional duality, and clinical prospects
    Kui Zhong, Qiang Yi, Zheng Chen, Yongchang Xu, Yangneng Zeng, Jinghua ZHONG · 2026 · Journal of Translational Medicine
58. TARGETED SEARCH FOR INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR BY MOLECULAR DOCKING AND MOLECULAR DYNAMICS METHODS IN A SERIES OF HYDROXYPHENYL DERIVATIVES OF 4-OXOPYRIMIDINEBENZSULFONAMIDE
    Oleg Ivanovich Kit, Ivan P. Kodonidi, Alexander A. Glushko, Elena Mikhaylovna Frantsiyants, Denis Stanislavovich Anenko, Irina V. Kaplieva, A. Chiriapkin, Polina Sergeevna Kachesova · 2025 · INDIAN DRUGS
59. Exploiting intracellular oncogenic proteins to release cytotoxins
    Matthias Schild, Dennis G. Gillingham · 2026 · RSC Medicinal Chemistry
60. Multi-specific antibody drug conjugate: The next frontier for solid tumors
    Xuyang Hao, Xiangyu Wu, Xin Yang, Hongqian Guo, Rong Yang · 2026 · Chemical Engineering Journal
61. Lipids regulate epidermal growth factor receptor activation by its ligands
    J.M.S. Hutchison, Mark A. Lemmon · 2026 · Biochemical Society Transactions
62. Exploring the potential of heterocyclic-containing tail approach in the development of novel covalent inhibitors dual-targeting EGFR and HER-2: design, synthesis and biological evaluation
    Shuang Hao, Jing-han Yan, Rui Wang, Gong‐hui Ge, Meng-chen Si, Yi-fan Niu, Zheng-hao Cai, Weixin Zheng, Chen-guang Zhao, Xin Li et al. · 2026 · Bioorganic & Medicinal Chemistry
63. TGF-α/EGFR-mediated lymphatic metastasis reveals a repositionable therapeutic target in breast cancer
    Wenyang Shi, Yueyun Pan, Bhavik Rathod, Yuhan Wang, Zhi Wang, Jianyu Shen, Francesca Gatto, Mingzhi Liu, Yizhe Sun, Margareta Wilhelm et al. · 2026 · npj Breast Cancer
64. Comprehensive genomic landscape of ERBB2 in Chinese GI tumors: mutation-centered landscapes and precision treatment opportunities
    Yinan Shi, Xiaoxuan Wang, Xiaotong Xi, Mengxiao Wang, J H Guo, Xing Zhang, Dongsheng Chen, Wenhui Yang · 2026 · Therapeutic Advances in Medical Oncology
65. Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2 -Mutant Non–Small Cell Lung Cancer
    Christine Marie Lovly, Christina Baik, Misako Nagasaka, Tejas Patil, Sonia S. Maruti, Stephen A. Stanhope, Neslihan Arife Kaya, Stephan Herbertz, Beth Nordstrom, Kathryn Evans et al. · 2026 · JCO Precision Oncology
66. Oncogenic EGFR Signaling as a Central Regulator of Chemoresistance in Ovarian Cancer: A Mechanistic Review
    Arulkumar Nagappan, Veeran Sethuraman, P. Parthiban, Jothi Nedunchezhian, Arvind Kumar Shukla · 2026 · International Journal of Molecular Sciences
67. Oncogenic EGFR rewires STING-TBK1 signalosomes to license DNA damage tolerance in NSCLC
    Qin Shen, Mei Chen, Yidan Chen, Qian Zhang, Qingzhe Wu, Xinyuan Yu, Fei Zhang, Shengduo Liu, Chen Chen, Cunqi Ye et al. · 2026 · The EMBO Journal
68. Research progress of small molecule protein kinase inhibitors (SMKIs) in the treatment of colorectal cancer: mechanism, application, and future prospects
    Lu Liu, 陈颖君, Mingxin Guo, Fan Yun, Xifeng Li, Le Chen, Y M Li, Feng Li · 2026 · Frontiers in Pharmacology
69. A Screening-Guided Biomimetic Exosome-Liposome Hybrid Nanoplatform Enables Pyroptosis-Enhanced Immune Reprogramming in Glioblastoma
    Yue Wang, Ru Zhao, Liming Miao, Jie Bian, Yiyao Zhou, Xiaoyu Zhao, Wei Song, Yue Wang, Xiue Jiang · 2026 · ACS Nano
70. Le récepteur HER3 ou ERBB3
    Christel Larbouret, Nadège Gaborit, Marie‐Alix Poul, André Pèlegrin, Thierry Chardès · 2015 · médecine/sciences
71. Novel Mechanisms of Resistance to Investigational Molecularly Targeted Drugs
    Kohji Noguchi · 2017 · YAKUGAKU ZASSHI
72. PROGNOSTIC BIOMARKERS IN TRIPLE NEGATIVE BREAST CANCER AS A POTENTIAL TARGET FOR FUTURE DRUG DISCOVERY
    Mekhla Gupta, Sanjeev Gupta, Rajesh Kumar Singh, Seema Khanna · 2017 · Asian Journal of Pharmaceutical and Clinical Research
73. Novel Non–HER2-targeted Therapies in HER2+ Breast Cancer
    Marina Nasrin Sharifi, Ruth M O'Regan · 2018 · Elsevier eBooks
74. Biology and Genetics of Breast Cancer
    Mustafa Emre Gedik, Ayse Lale Dogan · 2019 · Springer eBooks
75. A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma
    Jing Yang, Yanfei Yang, Yuquan Wei, Xiawei Wei · 2023 · Frontiers of Medicine
76. Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer
    Mukaddes Yılmaz, Eda Erdiş, Mahmut Uçar, Necla Demir, Celal Alandağ, Birsen Yücel · 2024 · Japanese Journal of Clinical Oncology
77. Protective effect of Sasa veitchii extract against all-trans-retinoic acid-induced inhibition of proliferation of cultured human palate cells.
    Yosuke Tsukiboshi, Yurie Mikami, Hanane Horita, Aya Ogata, Azumi Noguchi, Satoshi Yokota, Kenichi Ogata, Hiroki Yoshioka · 2024 · PubMed Central
78. Identification of new tissue markers for the monitoring and standardization of penile cancer according to the degree of differentiation.
    Carlos Casanova-Martín, Diego Liviu Boaru, Oscar Fraile‐Μartinez, Cielo García Montero, Diego De León-Oliva, Patricia De Castro-Martinez, M.J. Gimeno, Julia Buján, Natalio García‐Honduvilla, Luis G. Guijarro et al. · 2025 · PubMed
79. Application of Mendelian randomized research method in oncology research: bibliometric analysis
    Jiahao Chen, Yunli Wang, Rongsheng Jiang, Yawei Qu, Yan Li, Yang Zhang · 2024 · Frontiers in Oncology
80. Cilostazol alleviates imatinib-induced myocardial injury in rats by modulating the TGF-β1/MAPK, SHC/Grb2/SOS signaling pathways and upregulating miRNA-195-5P
    Basel A. Abdel‐Wahab, Ehab A. M. El‐Shoura, Saad Misfer Alqahtani, ‏Hebatallah M. Saad, Marwa B. Bakir, Dalia K. Zaafar · 2025 · Naunyn-Schmiedeberg s Archives of Pharmacology
81. A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of A140 Injection and Cetuximab (Erbitux®) in Healthy Chinese Male Subjects
    Jia Yin Xu, Junyou Ge, Yaling Li, Shu-Lin Liu, Sicong Li, Jing Si, Juncheng Liu, Xiaoxue Zhu, Yanhua Ding · 2025 · Advances in Therapy
82. High expression of DGKA indicates poor overall survival of nasopharyngeal carcinoma
    Hao Hui Chen, Runduan Lin, Qi Yuan, Xiaohang Gao, Lin Zhang, Rong Zhang · 2025 · Discover Oncology
83. Targeted Therapies for Neuroendocrine Neoplasms
    Heloisa Prado Soares, Jonathan Strosberg · 2016 · Springer eBooks
84. Co-targeting cancer stem-like cells and bulk cancer cells with a bispecific antibody
    Shi Hu · 2017 · Molecular & Cellular Oncology
85. The Cause of ErbB2 Receptor Resistance to Downregulation
    Elena I. Shramova, Galina M. Proshkina, Sergey Mikhailovich Deyev · 2018 · Russian Journal of Bioorganic Chemistry
86. Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer
    Evanthia T. Roussos Torres, Roisín M. Connolly · 2018 · Current Breast Cancer Reports
87. CARF: A Stress, Senescence, and Cancer Regulator
    Caroline Cheung, Rajkumar Singh Kalra, Sunil C. Kaul, Renu Wadhwa · 2019 · Elsevier eBooks
88. Afatinib
    Giuseppe Tridente · 2017 · Elsevier eBooks
89. Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
    Chun‐Chia Cheng, Po‐Jui Hsu, Zong‐Lin Sie, George T.Y. Chen · 2020 · Journal of Visualized Experiments
90. Molecular targets in GI malignancies – A pathologist's perspective
    Atul Sharma, Satyajit Pawar · 2021 · Indian Journal of Pathology and Microbiology
91. Next-generation sequencing-based detection in a breast MMPMN patient with EGFR T790M mutation: a rare case report and literature review
    Huiyun Lv, Aijuan Tian, Shanshan Zhao, Jinbo Zhao, Chen Song · 2023 · Frontiers in Oncology
92. A mathematical model for phenotypic heterogeneity in breast cancer with implications for therapeutic strategies
    Xin Li, Dave Thirumalai · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
93. Understanding the effects of therapeutic HER2 antibodies trastuzumab and pertuzumab on HER2-mediated cell signaling
    Hamid Maadi · 2020 · ERA: Education and Research Archive (University of Alberta)
94. Manipulating the hypoxic tumour microenvironment to study therapy resistance
    Jonathan Ient · 2021 · Research Publications (Maastricht University)
95. Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation
    Raphael Trenker, Devan C. Diwanji, Tanner Bingham, Kliment A. Verba, Natalia Jura · 2023 · eLife
96. [Progress in the study of Her2-targeted cancer therapeutic antibodies].
    Liang Chang, Chenhui Li, Jian Gao · 2015 · PubMed
97. Combined use of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) as target therapy in non-small cell lung cancer (NSCLC)
    Daniele Cretella · 2015 · DSpaceUnipr (University of Parma)
98. Molecular Regulation of Embryonic Mammary Gland Development
    Maria Voutilainen · 2015 · Työväentutkimus Vuosikirja
99. ERBB4 mutations in cancer and amyotrophic lateral sclerosis
    Kari J. Kurppa · 2014 · UTUPub (University of Turku)
100. Optimizing the Management of Metastatic HER2-Positive Breast Cancer
     Shom Goel, Sara M. Tolaney · 2015 · Current Breast Cancer Reports